September 2018, Self-screen successfully passed the transition to the ISO13485:2016 standard

July 2018, Focal trial shows significantly lower CIN3+ incidence for women primary screened for HPV compared to cytology

May 2018, United States Patent and Trademark Office grants patent of methylation markers PRDM14 and FAM19A4 to Self-screen B.V.

April 2018, QIAsure presented at the Polish Society of Colposcopy and Cervical Pathophysiology

November 2017, validation of The HPV-Risk assay on the Valgent-3 panel

October 2017, Eurogin congress Amsterdam